Literature DB >> 16149863

Photophysical, photochemical, and tumor-selectivity properties of bromine derivatives of rhodamine-123.

Silvia H D Lacerda1, Bindu Abraham, Thomas C Stringfellow, Guilherme L Indig.   

Abstract

The conceptual basis for the development of mitochondrial targeting as a novel therapeutic strategy for both chemotherapy and photochemotherapy of neoplastic diseases rests on the observation that enhanced mitochondrial membrane potential is a common tumor cell phenotype. The potential of this strategy is highlighted by the fact that the toxic effects associated with a number of cationic dyes known to localize in energized cell mitochondria are much more pronounced in tumor cells than in normal cells. Here we evaluate the phototoxic properties of four bromine derivatives of rhodamine-123 toward human uterine sarcoma (MES-SA) and green monkey kidney (CV-1) cells and compare the degrees of tumor cell selectivity associated with these dyes with those associated with two model mitochondrial triarylmethanes (crystal violet and ethyl violet). Selective phototoxicity toward tumor cells was found to be highly dependent upon the lipophilic/hydrophilic character of the cationic photosensitizer. Our experimental data have indicated that the probability of success of mitochondrial targeting in (photo)chemotherapy of neoplastic diseases is higher when the octan-1-ol/water partition coefficient of the drug candidate falls within approximately two orders of magnitude from that of the prototypical mitochondria-specific dye rhodamine-123.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16149863     DOI: 10.1562/2005-08-05-RA-639

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  5 in total

1.  Biodistribution and stability studies of [18F]fluoroethylrhodamine B, a potential PET myocardial perfusion agent.

Authors:  Vijay Gottumukkala; Tobias K Heinrich; Amanda Baker; Patricia Dunning; Frederic H Fahey; S Ted Treves; Alan B Packard
Journal:  Nucl Med Biol       Date:  2010-02-10       Impact factor: 2.408

2.  Biological characterization of F-18-labeled rhodamine B, a potential positron emission tomography perfusion tracer.

Authors:  Mark D Bartholomä; Huamei He; Christina A Pacak; Patricia Dunning; Frederic H Fahey; Francis X McGowan; Douglas B Cowan; S Ted Treves; Alan B Packard
Journal:  Nucl Med Biol       Date:  2013-09-04       Impact factor: 2.408

3.  (18)F-labeled rhodamines as potential myocardial perfusion agents: comparison of pharmacokinetic properties of several rhodamines.

Authors:  Mark D Bartholomä; Shaohui Zhang; Vamsidhar Akurathi; Christina A Pacak; Patricia Dunning; Frederic H Fahey; Douglas B Cowan; S Ted Treves; Alan B Packard
Journal:  Nucl Med Biol       Date:  2015-06-18       Impact factor: 2.408

4.  Synthesis of fluorine-18 labeled rhodamine B: A potential PET myocardial perfusion imaging agent.

Authors:  Tobias K Heinrich; Vijay Gottumukkala; Erin Snay; Patricia Dunning; Frederic H Fahey; S Ted Treves; Alan B Packard
Journal:  Appl Radiat Isot       Date:  2009-08-28       Impact factor: 1.513

5.  Effect of the prosthetic group on the pharmacologic properties of 18F-labeled rhodamine B, a potential myocardial perfusion agent for positron emission tomography (PET).

Authors:  Mark D Bartholomä; Vijay Gottumukkala; Shaohui Zhang; Amanda Baker; Patricia Dunning; Frederic H Fahey; S Ted Treves; Alan B Packard
Journal:  J Med Chem       Date:  2012-12-14       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.